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ABSTRACT 
Anti-viral chemotherapy plays an important part 
in treating and preventing influenza illness. How- 
ever, its effectiveness in severe infections can 
be debated and a reoccurring problem is the 
emergence of resistant virus. Passive immuni- 
sation has for a long time been and is still used 
for prophylaxis and treatment of a number of in- 
fectious diseases. In this experimental study 
anti-influenza antibodies were passively admin- 
istrated to mice, subsequently they were in- 
fected with influenza virus and treated with ose- 
ltamivir. The aim was to investigate, if anti-in- 
fluenza antibodies influenced the out come of 
oseltamivir treatment and development of re- 
sistance towards oseltamivir. We show, that ose- 
ltamivir alone was not able to effectively prevent 
a fatal outcome, but that oseltamivir adminis- 
tered together with a limited amount of antibod- 
ies, resulted in improvement of the clinical con- 
dition of the mice. The results also showed that 
a higher dosage of antibodies alone were able to 
protect the mice from a lethal dose of virus. 
These findings suggest that the effectiveness of 
oseltamivir depends on the host’s immune re- 
sponse to the influenza virus, and that that pas- 
sive immunization is an option that should be 
considered in the in control of influenza. 
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1. INTRODUCTION 
Passive immunisation has for a long time been and is 
still used for prophylaxis and treatment of a number of 
infectious diseases [1]. Since the 2009 pandemic, the 
proposal of using convalescent plasma as an early con- 
trol measurement, in a future influenza pandemic or as 
treatment for severely ill patients, has been raised by 
several voices [2-6]. 
Though there have been recent successful applications 
of passive immunisation as treatment for human influ- 
enza infections, in experimental settings [7-12], further 
investigations are warranted before it can be imple- 
mented in the control of influenza. Support for the pas- 
sive immunisation strategy also increases, as passive 
transfer of immune sera followed by lethal challenge in 
experimental animals, is becoming at standard in con-
firming new vaccines ability to provide protection [13- 
19]. 
Broadly cross neutralising or even potential universal 
monoclonal antibody that neutralises several different 
influenza subtypes has been identified. Passive transfer 
treatment with such anti-influenza antibodies or conva- 
lescent plasma administration, may not only be effective 
in preventing disease but could also minimize transmis- 
sion of the virus and therefore have influence on the 
spread of the virus during a future pandemic [14,20-22]. 
However, the use of such antibodies is expected to be 
expensive and escape mutants may develop making such 
treatment less efficient. 
Oseltamivir is used for the treatment of influenza, and 
the drug remains one of the important strategies in the 
influenza pandemic preparedness. Thus development of 
resistance to oseltamivir is an important issue. Initial cli- 
nical studies after introduction of the drug revealed that 
emerging of resistance to oseltamivir during treatment 
was much more common in children (0% - 27.3%) than 
in adults (0% - 4%) [23-28]. Immunocompromised pa- 
tients also showed elevated rates of resistance (13.3% - 
33.3%) [29,30]. 
The increased risk of oseltamivir resistance mutations 
in children and immunocompromised patients could re- 
flect that they are immunologically naïve. This absence 
of immunity against influenza A, in the beginning of an  
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infection, leads to a higher level of virus replication, which 
in turn leads to an augmentation in the number of muta- 
tions. This implies an increased risk of oseltamivir resis- 
tant mutants, which can be extrapolated to at pandemic 
situation where the population at large is naive. 
Influenza viral infection is not a natural disease in 
mice, thus these animals have no existing immune re- 
sponse to influenza virus. Influenza infections in these 
animals are therefore comparable to young children that 
are infected with influenza for the first time and with 
adults who get infected with a new pandemic virus, to 
which they have no prior immunity. 
In this work we investigated the dosage dependent ef- 
fect of administrated antibodies with regard to morbidity 
and mortality from an otherwise lethal influenza infec- 
tion. And we investigated the relationship of immune 
status on the effect of oseltamivir, including development 
of resistance, in BALB/c mice with a severe influenza 
infection. 
The susceptibility of mice to influenza viruses varies 
among the different mouse strains, but it also depends on 
the influenza strain [31,32]. In this model for severe in- 
fluenza infection we chose BALB/c mice, as they are 
known to get severe lung infection when infected with 
mouse pathogenic influenza strains [33]. Furthermore, 
these mice are also widely used in testing of antiviral 
drugs against influenza [34-37] and vaccine studies [38- 
40]. Ison et al. have previously shown development of 
oseltamivir resistance in a BALB/c mouse model [41]. 
2. MATERIALS AND METHODS 
All experiments were approved by The National Ani- 
mal Ethics Committee according to Danish regulations 
on animal welfare (case nr. 2007/561-1379 and 2009/ 
561-1611). They were performed under bio safety level 2 
conditions and carried out at the animal facility, Statens 
Serum Institut with regard to the LD90 experiments, oth- 
erwise at the Biomedical laboratory, University of Sou- 
thern Denmark 
2.1. Virus and Antivirals 
The influenza A vaccine strain A/Puerto Rico/8/34 
(H1N1) (PR8) was propagated in Madin-Darby Canine 
Kidney (MDCK) cells to a 50% tissue culture infectious 
dose (TCID50) of 107/ml. Oseltamivir capsules 75 mg 
(Roche) were used for treatment of the mice. The powder 
was suspended in sterile water and administered orally, 
twice daily, to a final dose of 10 mg/kg bodyweight/day. 
The treatment was commenced 24 h after inoculation and 
continued for 5 days. 
2.2. Mice 
Female BALB/c O1a Hsd mice from Harland; 8 - 9 
weeks old at the time of inoculation were used. The mice 
were challenged by administrating 50 µl of a virus dilu- 
tion to each nostril. Prior to the intra nasal viral inocula- 
tion the mice were anesthetized with isofluran by inhala- 
tion for the 90% lethal dose (LD90) experiments. For the 
rest of the experiments the mice were anesthetized with a 
mixture of Propofol (0.15 ml per 20 g mice) and Mede- 
tomidine (0.02 ml per 20 g mice) given i.p. and their 
recovery was aided by Antisedan (0.10 ml per 20 g mice) 
i.p. 
There were 8 animals per cage in one of the shorter 
experiments, otherwise a maximum of 5 animals per 
cage. 
2.3. Surveillance of Clinical Illness and  
Human Endpoints 
After infection the mice were monitored a least every 
12th hour. At these time points they were weighed and 
their temperature was followed using either an electronic 
rectal probe or a subcutaneous chip and a handheld 
reader. In addition they were observed for clinical symp-
toms; ruffled fur, tweaked eyes, hyperventilation and 
isolation from the group. 
A weight loss of 20%, a temperature below 34˚C on 
two consecutive measurements or a temperature below 
32˚C once were used as humane endpoints at which the 
mouse was terminated. 
2.4. LD90 
A 10-fold dilution series of A/PR/8/34(H1N1) TCID50 
of 107/ml were made with sterile water and 6 groups of 8 - 
10 mice were inoculated (group 1: undiluted virus; group 
2: 10–1; group 3: 10–2; group 4: 10–3; group 5: 10–4 and 
group 6: 10–5). A control group of 3 mice received sterile 
water as inoculum. The mice from group 4 - 6 were bled 
prior to termination. The LD90 dose was determined by 
the Reed-Muench method [42]. 
2.5. Purifications of Antibodies for Passive 
Immunization 
Antibodies from mice infected with PR8 in the LD90 
experiment and a subsequent experiment with 30 mice, 
were purified from serum with the Montage® Antibody 
Purification Kit and Spin Columns with PROSEP®—A 
Media from Millipore. IgG concentrations were 1.32 
mg/ml and 12.5 mg/ml first and second purification re- 
spectively. 
2.6. Haemagglutination Inhibition (HAI) 
Assay 
HAI Assay of antibodies was performed according to 
standard protocols (WHO Manual on Animal Influenza  
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Diagnosis and Surveillance from 2002). Briefly, the an- 
tibodies were diluted initially 1:3 in receptor-destroying 
enzyme from Vibrio cholerae and incubated overnight at 
37˚C. The receptor-destroying enzyme was there after in- 
activated at 56˚C for 30 min. Another six volumes of 
isotonic saline was added to give a final dilution of anti- 
bodies of 1:10. The diluted antibodies were tested for 
non-specific agglutinins, and were negative. 
A two fold serial dilutions of antibodies were pre-in- 
cubated with 8 haemagglutination units of virus per well. 
The content of the plate was mixed by manual agitation 
and incubated for 15 minutes at room temperature. Gui- 
nea pig red blood cells were added to a final concentra- 
tion of 0.75%, after which the plate was mixed again by 
manual agitation and incubated at room temperature for 
60 min. The HAI titer is the reciprocal of the last dilu- 
tion of antiserum that completely inhibits haemaggluti- 
nation. 
2.7. Titration of Antibodies in Mice 
Three groups of five mice were immunised i.p. 3 days 
prior to inoculation with PR8. They received an amount 
of antibodies corresponding to 14 HAI (46.2 μg), 28 HAI 
(92.4 μg) and 42 HAI (138.6 μg) respectively. The anti- 
bodies were diluted in sterile NaCl 0.9%, to a total vol- 
ume of 100 µl. A fourth group was injected with isotonic 
saline as a control; this group was not challenged with 
virus. In a second experiment, a group of 5 mice received 
antibodies from a second purification corresponding to 
21 HAI (82.0 μg) i.p., again 3 days prior to inoculation 
with A/PR8/34(H1N1). All mice in the challenged 
groups were inoculated with an LD90 dose of A/PR/ 
8/34(H1N1). 
2.8. Oseltamivir and Passive Immunisation 
Experiment 
Four groups of mice were all inoculated with an LD90 
dose of A/PR/8/34(H1N1). One group of two mice re- 
ceived no further treatment. A second group of two mice 
were immunised i.p. 3 days prior to inoculation with an 
amount of antibodies corresponding to 14 HAI. The third 
and fourth groups contained 13 mice each, which all re- 
ceived oseltamivir treatment, group 4 was in addition 
immunised i.p. 3 days prior to inoculation like group 2. 
Pharyngeal swabs were taken from all mice daily, with 
Minitip Flocked Swabs (microRheologics) and stored in 
phosphate buffered saline, in order to quantitate the vi- 
rus by real-time PCR. 
2.9. RNA Extraction 
Viral RNA was extracted from 200 μl of mouse pha- 
ryngeal swab suspension or from 200 μl of 10 fold dilu-  
tions of the cultured A/PR8/34(H1N1) virus, by an auto- 
mated MagNA Pure LC Instrument applying the MagNA 
Pure LC Total Nucleic Acid Isolation Kit (Roche Diag- 
nostics), elution volume was 100 μl. 
2.10. Real-Time PCR 
The real-time RT-PCR was set up using the OneStep 
RT-PCR Kit (QIAGEN) along with primers and a FAM 
labelled probe targeting the matrix gene. Five µl purified 
nucleic acid was added to 20 µl mastermix. The RNA 
sequence was amplified on an Mx3005p thermocycler 
(Stratagene) using the following programme: 20 min at 
50˚C (RT-step), 15 min at 95˚C (denaturation of the DNA 
polymerase), 45 cycles of: [15 sec at 95˚C (denaturation), 
60 sec at 55˚C (annealing and extension)]. 
2.11. Sanger Sequencing 
A 200 bp sequence around the H274Y mutation site in 
the NA gene, was amplified using the OneStep RT-PCR 
Kit (QIAGEN), using the following program: 30 min at 
50˚C (RT-step), 15 min at 95˚C (denaturation of the DNA 
polymerase), 45 cycles of: [30 sec at 94˚C (denaturation), 
30 sec at 58˚C (annealing) 2 min at 72˚C (extension)] 
followed by 10 min at 72˚C. 
Five µl purified nucleic acid was added to 45 µl mas-
termix (F-primer: GGCTGGCCTCGTACAAAAT and 
R-primer: CCCCACTGCAGATGTATCCT). 
PCR products were purified using the GFX™ PCR 
DNA or Gel Band Purification Kit (GE Healthcare) prior 
to sequencing. For some of the samples it was necessary 
to perform a nested PCR, to get sufficient product.  
The first PCR was performed as above with the follow-
ing primers; 
Forward: TATTACGCGTCAGGAGCAAAAGCAGG- 
AGT 
Reverse: ATATGGCGCCGTATTAGTAGAAACAAG- 
GAGTTTTTT. 
The second PCR was performed on 5 µl of the first 
PCR reactions as template and was run like above. 
The sequencing reaction was performed by ABI 
PRISM® BigDye™ Terminators v1.1 Cycle Sequencing 
Kit (Applied Biosystems) using 25 ng template, accord-
ing to the following program: 2 min at 96˚C (denatura-
tion), 25 cycles of: [10 sec at 96˚C (denaturation), 5 sec 
at 50˚C (annealing) 4 min at 60˚C (extension)]. They 
were developed on an automatic ABI PRISM® 3130 ge- 
netic analyzer (Applied Biosystems) with 80 cm capilla- 
ries. 
The basecalling in the electropherograms was verified 
in Sequence Scanner software (Applied Biosystems). Se- 
quence assembly, multiple alignment and alignment trim- 
ming were performed with the BioEdit software v.7.0.0. 
Copyright © 2012 SciRes.                                                                    OPEN ACCESS 
B. N. J. Pourroy et al. / Health 4 (2012) 933-940 936 
2.12. Statistics 
The p-values for the survival data, was calculated us- 
ing Fisher’s exact one tailed probability test. α < 0.05 
was considered significant. 
3. RESULTS 
3.1. Lethal Infection 
A lethal infection model with influenza A virus A/PR/ 
8/34(H1N1) was established in BALB/c mice, without 
prior adaption. The LD90 titer was established using the 
humane endpoints; 20% weight loss, temperature below 
34˚C on two consecutive measurements or temperature 
below 32˚C, as surrogates for death. Survival curves 
from titration of influenza virus in the mice can be seen 
in Figure 1, along with the changes in body weight for 
three of the groups. Infection with undiluted virus 
(TCID50: 107/ml) gave a very rapid onset of clinical ill-  
 
 (a) 
(b) 
 
Figure 1. LD90 experiment. 6 groups of mice were inoculated 
intranasally with a 10 fold titration from the undiluted TCID50: 
107/ml A/PR/8/34(H1N1) to TCID50: 101/100 µl respectively, to 
determine the LD90 dosage. Panel A pictures the survival of the 
mice from the 6 groups and panel B presents the average wei- 
ght loss in percent for the three groups receiving the lowest do- 
sages. 
ness, and after only 30 h most of the mice were terminally 
ill. In the mice inoculated with virus diluted to TCID50: 
105/100 µl or 104/100 µl the symptoms were delayed 
with approximately 18 h, but all together these infections 
resulted in LD100 after only 55 h. Group 4 received vi- 
rus diluted to TCID50: 103/100 µl. The mice in this group 
did not begin to display signs of clinical illness until after 
56 h and LD100 was reached on day 6. The onset of ill- 
ness was delayed even further for group 5, where mice 
were challenged with virus diluted to TCID50: 102/100 µl. 
In this group 3 mice recovered and lived at day 9, when 
the experiment ended. The last group received virus di- 
luted to TCID50: 101/100 µl. These mice did, with the 
exception of 2, not show any signs of clinical illness, and 
all survived to day 9. LD90 titer of the virus was deter- 
mined to be 103.33/ml. 
3.2. Passive Immunisation 
In an initial immunisation experiment antibodies were 
titrated in mice, 15 control mice were challenged without 
prior immunisation. Of these 15, one survived to day 11 
(7%). In the immunisation groups of 5 mice, 14, 28 and 
42 HAI units of antibodies against the virus were given 
respectively, three days before viral inoculation. From 
the first group none (0%) of the mice survived past day 9 
and the severity of the illness was similar to the group 
without any prior immunisation. In the groups receiving 
double and triple dose 4 and 5 mice, respectively, sur- 
vived to day 11 (80% and 100%). Survival curves and 
the changes in body weight, from the antibody titration is 
illustrated in Figure 2. These differences are statistically 
significant with a P-value of 0.0049 for the double dose 
group and 0.0003 for the triple dose group, compared to 
the control group respectively. Some of these mice did 
show symptoms of influenza illness, but apart from the 
one that was terminated all recovered.  
The mice in an immunisation control group showed no 
adverse effects with regard to weight or temperature nor 
with regard to the other clinical symptoms described 
above. 
In the subsequent experiment all (100%) of the mice 
immunised with 21 HAI units of antibodies, from the 
second purification, survived to day 13 (see Figure 2) 
and they showed no signs of illness, whereas none of the 
mice that, in this second experiment, were challenged 
without prior immunisation survived past day 5 (0%) 
(data not shown). This is a statistically significant dif-
ference with a P-value of 0.0003, compared to the con- 
trol group. 
3.3. Oseltamivir and Passive Immunisation 
Experiment 
In the “virus only” control group two mice were in- 
fected with A/PR/8/34(H1N1). Both of these were ter-  
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Figure 2. Passive immunisation experiments. Four groups of 
mice were respectively immunised with 14, 28 and 42 HAI 
units of antibodies against A/PR/8/34(H1N1), three days prior 
to inoculation with the same virus. Two control groups were in- 
cluded; one group (imm only) was injected with isotonic saline 
at the time of immunisation and was not challenged with virus. 
The other control group (virus only) was challenged with virus 
but not immunised. The data summarises two experiments and 
the antibodies used to immunise the 21 HAI units group was 
from a different purification and the immunisation was per-
formed in the 2 experiments. Panel A pictures the survival of 
the mice from the 6 groups and panel B presents the average 
weight loss in percent. *P = 0.0003, **P = 0.0049. 
 
minated after 4 days. In the other control group “immu- 
nisation” the mice had received antibodies prior to infec- 
tion; these two mice were terminated after 5.5 days, so 
the immunisation dosage had the desired effect of con- 
veying some protection without hindering the course of 
infection. Comparing the two oseltamivir treated groups 
“oseltamivir” and “immunisation + oseltamivir” we ob- 
served a clear effect of the antibodies, as 10 out of 13 
mice (76.9%) in the immunised the group survived to day 
9, opposed to 3 out of 13 (23%) in the group which only 
received oseltamivir (see survival curves in Figure 3). 
The difference between the two groups is statistically  
 (a)
(b)
 
Figure 3. Oseltamivir/passive immunisation experiment. Two 
investigate whether circulating anti A/PR/8/34(H1N1) antibod- 
ies prior to challenge with A/PR/8/34(H1N1) virus could en-
hance the effect of oseltamivir; two groups of mice were inocu- 
lated with A/PR/8/34(H1N1). Tree days earlier, one of the 
groups had been immunised passively with 14 HAI units of 
antibodies against the virus (imm + oselt) the other group (oselt) 
was not immunised. Both groups received oseltamivir treat-
ment for 5 days, starting at day one. Two control groups were 
included; one group (imm) was also immunised passively with 
14 HAI units of antibodies against the virus tree day before 
challenge. The other control group (virus only) was challenged 
with virus, but not immunised. The control groups were not 
treated with oseltamivir. Panel A pictures the survival of the 
mice from the 4 groups and panel B presents the average 
weight loss in percent. *Statistical significant difference, be-
tween the two groups (P = 0.0085). 
 
significant with a P-value of 0.0085. All the mice in the 
“oseltamivir” and “immunisation + oseltamivir” groups 
tested positive for influenza A virus by real-time PCR 
analyses on one or several days. We tried to monitor the 
viral load in the mice over the 9 days the experiment 
lasted, but probably due to technical difficulties in ob-
taining comparable material from the pharyngeal swabs, 
this was not possibly in a reliably way (Data not show). 
The sequence analysis on the virus specimens from the 
pharyngeal swabs showed no evidence of the oseltamivir 
resistance mutation H274Y in either group. 
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3.4. Humane Endpoints 
A review of the criteria for termination shows that in 
the two passive immunisation experiments and in the 
oseltamivir/passive immunisation experiment only three 
mice were terminated on the basis of a temperature be- 
low 34˚C on two consecutive measurements and none on 
the basis of a temperature below 32˚C once. All three 
were at the point of termination very close to the weight 
loss limit. 
In the LD90 experiments with the three highest dosages 
the temperature was more often the basis for the decision 
to terminate. 
4. DISCUSSION 
In the 1918 pandemic plasma from convalescent pa- 
tients was in some cases used to treat other patients with 
severe illness. In a meta-analysis of these studies Luke et 
al. [43] concludes that the patients “may have experi- 
enced a clinical important reduction in the risk of death”. 
Since the idea of passive immunisation as treatment for 
severe influenza has continued to re-emerge from time to 
time without really being put to the test or offered as a 
general treatment. Antiviral treatment of the avian influ- 
enza H5N1 with oseltamivir was reported to decrease the 
fatalities from 88% (49/56) in patients not receiving an- 
tiviral treatment to 53% (100/188) [44]. However, no 
randomized controlled study exists and these groups of 
patients are hardly comparable. 
The issue of emergence of oseltamivir resistance dur- 
ing treatment of H5N1 is not addressed in any large study. 
de Jong et al. describes that despite treatment with osel- 
tamivir at least two of eight developed the H274Y resis- 
tance mutation in a Vietnamese study [45]. Giving us an 
indication that development of oseltamivir resistance 
might occur frequently in H5N1 infections in man. De- 
spite the fact that oseltamivir may not be very effective 
in severe infections, it is still of great concern that resis- 
tance towards it seem to develop rather rapidly. An al- 
ternate treatment option lies in passive immunisation or a 
combination of passive immunotherapy and antiviral 
treatments. Wang et al. points out the need for more re- 
search into such combination strategies after one off their 
patients recovered after receiving oseltamivir and post- 
vaccination plasma [11]. Other recent settings where 
experimental treatment with IgG or convalescent plasma 
were given to humans, also found it to be protective [7, 
8,10-12]. 
Several monoclonal antibodies against the stem loop 
of the haemagglutinin have lately been produced. These 
antibodies react against conserved epitopes of the influ- 
enza virus surface protein and have shown to be effective 
in animal challenge models [46]. However, if such anti- 
bodies are to be used in humans they will probably  
needed to be humanized and as we have seen with other 
therapeutic antibodies they will be very expensive. For 
therapeutics the monoclonal antibodies may have to be 
combined in order to reduce the likelihood of antigenic 
drift and thereby resistance towards the effect of such 
antibodies. Polyclonal antibodies are easy to obtain and 
produce from reconvalesent persons, are relative inex- 
pensive, easy to administrate and are not likely to cause 
significant resistance towards its effect. 
With this study we aimed to examine the influence of 
immune status on the effect of oseltamivir and the de- 
velopment of resistant mutants, by administering poly- 
clonal reconvalesent anti-influenza antibodies, in an ex- 
perimental model of severe influenza infection. 
Our results show that we were able to protect mice 
from death and even clinical illness, by passive immuni- 
sation, with IgG from mice previously infected with the 
same strain, in a dosage dependant manner. No adverse 
effects of the immunisation were detected in the control 
group. This finding is in agreement with several studies 
that have been conducted in animals, investigating the 
prophylactic and therapeutic effects of passive immuni- 
sation in cases of severe influenza infection [47-49]. The 
amount of antibodies needed to convey 80% and 100% 
protection in our study were considerably lower, than the 
ones described by Király et al. [50]. 
An immunisation dosage (14HAI) that had the desired 
effect of conveying some protection, without hindering 
the course of infection and in this way simulating a lim- 
ited immunity was determined. We showed that even this 
very limited antibody protection, which on its own was 
not sufficient to rescue the mice from a fatal outcome, 
enhanced the clinical effect of oseltamivir treatment and 
increased the survival of mice. These findings suggest 
that the effectiveness of oseltamivir depends on the host’s 
immunological memory. 
A combination therapy of convalescent polyclonal 
anti-influenza IgG and oseltamivir also reduced mortality 
in patients with severe influenza A infection, in a pro- 
spective cohort study by Hung et al. [9], during the 2009 
pandemic. 
In our experiments we did not detect oseltamivir re- 
sistant viruses in our animals. However, from studies in 
humans we know that immunocompromised patients and 
immunological naïve patients are at risk of developing 
resistant viruses. We think that a timely administration of 
polyclonal antibodies may help to reduce this risk. 
5. CONCLUSIONS 
In our study we show that passive administration of 
antibodies can protect mice from a lethal infection with 
influenza A viruses. Furthermore, we were able to show 
that sub-protective dosages of antibody in combination 
with oseltamivir were more effective in saving the ani- 
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mals than one of these treatment options alone. 
Passive immunization with polyclonal anti-influenza 
IgG is an option that should be considered in a pandemic 
situation for severe cases of influenza infection, espe- 
cially for high risk patients in combination with antiviral 
treatment. 
In a future experiment we suggest to evaluate the pro- 
tection level in a study were IgG are administered the- 
rapeutically for example one or two days post infection. 
Also the prophylactic use of polyclonal anti-influenza 
antibodies to patients that due to immunosuppression 
don’t respond normal influenza vaccines should be ex- 
plored. 
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